Wednesday, June 10, 2026
πŸ‡ΊπŸ‡Έ FDA

pharma Β· No medical condition. Β· Generalized Myasthenia Gravis

Anaxis Pharma

Lacuna Pharma Pty Ltd

Anaxis Pharma clinical programs β€” 198 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Melbourne, AU HQ
2017 Founded
7 Employees
TGA registrant Type
Company details
Status
Public
HQ
Melbourne, AU
Founded
2017
Employees
7
Programs
642
Drugs
673
Patents
0
Official website β†— All projects Drug pipeline News & analysis
Intelligence Β· Clinical Programs

Anaxis Pharma projects

198 ClinicalTrials.gov programs sponsored by Anaxis Pharma.

Anaxis Pharma has 198 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

198 programs

Clinical programs

Page 4 of 5

  1. Powder for reconstitution for enteral administration

    Lacuna Pharma Pty Ltd

    Intestinal Malabsorption

    phase 3 small molecule active

    1 trial

  2. Pozelimab, Cemdisiran

    Lacuna Pharma Pty Ltd

    Paroxysmal nocturnal hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  3. QL2107, PEMBROLIZUMAB

    Lacuna Pharma Pty Ltd

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  4. R2810-ONC-16113

    Lacuna Pharma Pty Ltd

    Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  5. R2810-ONC-1624

    Lacuna Pharma Pty Ltd

    Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  6. R2810-ONC-1788

    Lacuna Pharma Pty Ltd

    Cutaneous Squamous Cell Carcinoma (CSCC)

    phase 3 small molecule active

    1 trial

  7. R3767-ONC-2011

    Lacuna Pharma Pty Ltd

    Melanoma

    phase 3 small molecule active

    1 trial

  8. R3767-ONC-2235

    Lacuna Pharma Pty Ltd

    Advanced Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  9. R3918-AMD-2326

    Lacuna Pharma Pty Ltd

    Geographic Atrophy Secondary to Age-Related Macular Degeneration

    phase 3 small molecule active

    1 trial

  10. R3918-PNH-2021

    Lacuna Pharma Pty Ltd

    Paroxysmal nocturnal haemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  11. R5458-ONC-2246

    Lacuna Pharma Pty Ltd

    Relapsed Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  12. R668-AD-1434

    Lacuna Pharma Pty Ltd

    Atopic Dermatitis

    phase 3 small molecule active

    1 trial

  13. R668-BP-1902

    Lacuna Pharma Pty Ltd

    Bullous Pemphigoid

    phase 3 small molecule active

    1 trial

  14. R7508-DVT-24116

    Lacuna Pharma Pty Ltd

    Thromboembolic disease

    phase 3 small molecule active

    1 trial

  15. R7508-DVT-24120

    Lacuna Pharma Pty Ltd

    Symptomatic Venous Thromboembolism (VTE)

    phase 3 small molecule active

    1 trial

  16. RA101495-02.302

    Lacuna Pharma Pty Ltd

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  17. RANOLAZINE, FLECARDIA Διάλυμα Ξ³ΞΉΞ± ένΡση/έχχυση

    Lacuna Pharma Pty Ltd

    Restoration of sinus rhythm in patients with recent AF onset

    phase 3 small molecule active

    1 trial

  18. REGN4461 - Mibavademab

    Lacuna Pharma Pty Ltd

    Monogenic obesity

    phase 3 small molecule active

    1 trial

  19. RM-493-035

    Lacuna Pharma Pty Ltd

    Improper function of certain messenger materials in the body that control body weight and hunger in people

    phase 3 small molecule active

    1 trial

  20. SHR-3680-III-HSPC

    Lacuna Pharma Pty Ltd

    Metastatic hormone-sensitive prostate cancer with high tumor load

    phase 3 small molecule active

    1 trial

  21. SHR3162-III-305

    Lacuna Pharma Pty Ltd

    Metastatic Castration-Resistant Prostate Cancer

    phase 3 small molecule active

    1 trial

  22. SHR8735-303

    Lacuna Pharma Pty Ltd

    Chemotherapy induced thrombocytopenia

    phase 3 small molecule active

    1 trial

  23. SL0044

    Lacuna Pharma Pty Ltd

    Systemic lupus erythematosus (SLE)

    phase 3 small molecule active

    1 trial

  24. SL0046

    Lacuna Pharma Pty Ltd

    Systemic lupus erythematosus (SLE)

    phase 3 small molecule active

    1 trial

  25. SMX 22-002

    Lacuna Pharma Pty Ltd

    Locally advanced or metastatic breast cancer

    phase 3 small molecule active

    1 trial

  26. SPI-BEL-301

    Lacuna Pharma Pty Ltd

    Peripheral T-Cell Lymphoma

    phase 3 small molecule active

    1 trial

  27. SY-1425-301

    Lacuna Pharma Pty Ltd

    Newly Diagnosed RARA-positive Adult Patients with Higher-risk Myelodysplastic Syndrome

    phase 3 small molecule active

    1 trial

  28. Sovateltide, Sovateltide matching placebo

    Lacuna Pharma Pty Ltd

    Acute cerebral ischemic stroke

    phase 3 small molecule active

    1 trial

  29. T89-08-ORESA

    Lacuna Pharma Pty Ltd

    Stable Angina Pectoris

    phase 3 small molecule active

    1 trial

  30. TASIMELTEON, HETLIOZ 20 mg hard capsules

    Lacuna Pharma Pty Ltd

    Non-24 Hour Sleep-Wake Disorder

    phase 3 small molecule active

    1 trial

  31. TAXOL for Recurrent or Metastatic HER2 Ne…

    Lacuna Pharma Pty Ltd

    Recurrent or Metastatic HER2 Negative Breast Cancer

    phase 3 small molecule active

    1 trial

  32. TILD-19-07

    Lacuna Pharma Pty Ltd

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  33. TILD-19-12

    Lacuna Pharma Pty Ltd

    Treatment of pediatric subjects with moderate to severe chronic plaque psoriasis

    phase 3 small molecule active

    1 trial

  34. TILD-19-19

    Lacuna Pharma Pty Ltd

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  35. TILD-24-01

    Lacuna Pharma Pty Ltd

    Moderate to Severe Genital Psoriasis

    phase 3 small molecule active

    1 trial

  36. TV48125-CNS-30084

    Lacuna Pharma Pty Ltd

    Episodic and Chronic Migraine

    phase 3 small molecule active

    1 trial

  37. Tradipitant

    Lacuna Pharma Pty Ltd

    Idiopathic or diabetic gastroparesis with moderate to severe nausea.

    phase 3 small molecule active

    1 trial

  38. Troriluzole, Troriluzole

    Lacuna Pharma Pty Ltd

    Obsessive Compulsive Disorder

    phase 3 small molecule active

    1 trial

  39. UGN-102 (Mitomycin)

    Lacuna Pharma Pty Ltd

    Non-Muscle Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  40. UGN-103 (Mitomycin)

    Lacuna Pharma Pty Ltd

    Nonmuscle Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  41. UGN-104

    Lacuna Pharma Pty Ltd

    Low-grade Upper Tract Urothelial Cancer

    phase 3 small molecule active

    1 trial

  42. URO-901-3007

    Lacuna Pharma Pty Ltd

    Neurogenic Detrusor Overactivity (NDO)

    phase 3 small molecule active

    1 trial

  43. UX143-CL301

    Lacuna Pharma Pty Ltd

    Osteogenesis imperfecta (OI)

    phase 3 small molecule active

    1 trial

  44. VP-VEC-162-3108

    Lacuna Pharma Pty Ltd

    Insomnia Disorder

    phase 3 small molecule active

    1 trial

  45. VP-VEC-162-3502

    Lacuna Pharma Pty Ltd

    Delayed Sleep-Wake Phase Disorder (DSWPD)

    phase 3 small molecule active

    1 trial

  46. Viltolarsen

    Lacuna Pharma Pty Ltd

    Duchenne Muscular Dystrophy (DMD)

    phase 3 small molecule active

    1 trial

  47. Zilucoplan sodium

    Lacuna Pharma Pty Ltd

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  48. bimekizumab

    Lacuna Pharma Pty Ltd

    Active juvenile idiopathic arthritis subtypes enthesitis-related arthritis (including juvenile-onset ankylosing spondylitis) and juvenile psoriatic arthritis

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Anaxis Pharma have?

198 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.